IDEXX Laboratories, Inc. vs ZIM Integrated Shipping Services Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while ZIM Integrated Shipping Services Ltd trades at $29.95 (market cap $3.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.1× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| IDXX | ZIM | |
|---|---|---|
Market Cap | $40.43B | $3.65B |
Volume | 692,164 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $766.68 | $30.51 |
52-Week Low | $504.70 | $12.44 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | $41.32B | $7.32B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
ZIM trades at $30.12, up 0.43% on the day and near its 52-week high of $30.96, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while fundamentals show mixed signals with a low P/S of 0.57 and EV/EBITDA of 3.81, but declining profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, though revenue and net income are trending lower year-over-year. Key news includes a pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creating significant event-driven uncertainty.
The investment case hinges on the acquisition outcome; approval could deliver immediate upside to $35, while rejection may pressure shares despite operational improvements. Risks include earnings volatility, geopolitical factors affecting the deal, and exposure to cyclical shipping rates. Analyst sentiment is cautious with no buy ratings, reflecting the binary nature of the takeover situation. The stock offers value on a sales basis but requires careful risk management due to the high-stakes merger dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →